Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXSMNASDAQ:CORTNASDAQ:JAZZNASDAQ:RPRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXSMAxsome Therapeutics$106.67+1.2%$106.63$72.21▼$139.13$5.25B0.46667,895 shs328,591 shsCORTCorcept Therapeutics$68.40-5.4%$72.87$29.42▼$117.33$7.24B0.151.18 million shs1.26 million shsJAZZJazz Pharmaceuticals$107.71-1.6%$108.96$95.49▼$148.06$6.53B0.32826,273 shs256,959 shsRPRXRoyalty Pharma$35.55-2.2%$33.88$24.05▼$36.43$20.04B0.53.67 million shs1.22 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXSMAxsome Therapeutics0.00%+1.93%-5.86%+6.96%+28.45%CORTCorcept Therapeutics0.00%-0.78%+4.38%-2.68%+141.52%JAZZJazz Pharmaceuticals0.00%+2.38%-1.52%+2.35%+8.07%RPRXRoyalty Pharma0.00%+1.27%+7.53%+17.06%+41.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXSMAxsome Therapeutics4.749 of 5 stars4.51.00.04.52.34.20.6CORTCorcept Therapeutics4.7058 of 5 stars3.51.00.04.32.74.21.9JAZZJazz Pharmaceuticals4.8966 of 5 stars4.51.00.04.02.73.32.5RPRXRoyalty Pharma4.8927 of 5 stars3.61.03.33.73.61.72.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXSMAxsome Therapeutics 3.06Buy$172.3361.57% UpsideCORTCorcept Therapeutics 3.00Buy$138.25102.12% UpsideJAZZJazz Pharmaceuticals 2.92Moderate Buy$184.0070.83% UpsideRPRXRoyalty Pharma 3.25Buy$47.3333.14% UpsideCurrent Analyst Ratings BreakdownLatest JAZZ, AXSM, RPRX, and CORT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025AXSMAxsome TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$190.006/12/2025AXSMAxsome TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/11/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.006/3/2025JAZZJazz PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$202.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/16/2025RPRXRoyalty PharmaMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$51.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/7/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$200.00 ➝ $180.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXSMAxsome Therapeutics$385.69M13.62N/AN/A$1.18 per share90.39CORTCorcept Therapeutics$675.04M10.74$1.18 per share58.19$6.49 per share10.54JAZZJazz Pharmaceuticals$4.07B1.60$29.84 per share3.61$67.72 per share1.59RPRXRoyalty Pharma$2.26B8.83$4.10 per share8.67$17.56 per share2.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXSMAxsome Therapeutics-$287.22M-$5.77N/A37.82N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)CORTCorcept Therapeutics$141.21M$1.1658.8936.97N/A19.33%20.40%16.64%8/4/2025 (Estimated)JAZZJazz Pharmaceuticals$560.12M$7.5014.385.764.7211.86%26.62%9.14%7/30/2025 (Estimated)RPRXRoyalty Pharma$858.98M$1.8519.277.321.8748.23%24.71%13.87%8/6/2025 (Estimated)Latest JAZZ, AXSM, RPRX, and CORT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025AXSMAxsome Therapeutics-$1.04N/AN/AN/A$140.02 millionN/A8/4/2025Q2 2025CORTCorcept Therapeutics$0.23N/AN/AN/AN/AN/A7/30/2025Q2 2025JAZZJazz Pharmaceuticals-$5.61N/AN/AN/A$1.05 billionN/A5/8/2025Q1 2025RPRXRoyalty Pharma$0.99$1.06+$0.07$0.41$724.69 million$839.00 million5/6/2025Q1 2025JAZZJazz Pharmaceuticals$4.65$1.68-$2.97-$1.52$984.16 million$897.84 million5/5/2025Q1 2025CORTCorcept Therapeutics$0.17$0.17N/A$0.17$177.93 million$157.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ACORTCorcept TherapeuticsN/AN/AN/AN/AN/AJAZZJazz PharmaceuticalsN/AN/AN/AN/AN/ARPRXRoyalty Pharma$0.882.48%N/A47.57%5 YearsLatest JAZZ, AXSM, RPRX, and CORT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/21/2025RPRXRoyalty Pharmaquarterly$0.222.7%5/16/20255/16/20256/10/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXSMAxsome Therapeutics3.482.031.96CORTCorcept TherapeuticsN/A3.072.96JAZZJazz Pharmaceuticals1.283.382.97RPRXRoyalty Pharma0.681.561.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXSMAxsome Therapeutics81.49%CORTCorcept Therapeutics93.61%JAZZJazz Pharmaceuticals89.14%RPRXRoyalty Pharma54.35%Insider OwnershipCompanyInsider OwnershipAXSMAxsome Therapeutics22.40%CORTCorcept Therapeutics20.50%JAZZJazz Pharmaceuticals4.30%RPRXRoyalty Pharma18.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXSMAxsome Therapeutics38049.24 million38.21 millionOptionableCORTCorcept Therapeutics300106.04 million84.31 millionOptionableJAZZJazz Pharmaceuticals2,80060.51 million57.91 millionOptionableRPRXRoyalty Pharma80562.24 million455.98 millionOptionableJAZZ, AXSM, RPRX, and CORT HeadlinesRecent News About These CompaniesRoyalty Pharma PLC (NASDAQ:RPRX) Shares Bought by Sumitomo Mitsui DS Asset Management Company LtdJuly 6 at 4:12 AM | marketbeat.comRoyalty Pharma PLC (NASDAQ:RPRX) Shares Bought by KBC Group NVJuly 4 at 4:08 AM | marketbeat.comSumitomo Mitsui Trust Group Inc. Sells 88,416 Shares of Royalty Pharma PLC (NASDAQ:RPRX)July 3, 2025 | marketbeat.comAllspring Global Investments Holdings LLC Purchases 21,729 Shares of Royalty Pharma PLC (NASDAQ:RPRX)July 3, 2025 | marketbeat.comRoyalty Pharma PLC (NASDAQ:RPRX) Shares Purchased by Mirae Asset Global Investments Co. Ltd.July 3, 2025 | marketbeat.comRoyalty Pharma PLC (NASDAQ:RPRX) Stake Reduced by New South Capital Management Inc.July 2, 2025 | marketbeat.comRoyalty Pharma (NASDAQ:RPRX) Sets New 52-Week High - Here's WhyJuly 1, 2025 | marketbeat.comRoyalty Pharma: Attractive Acquisition With Upside Risk/Reward On Current PipelineJuly 1, 2025 | seekingalpha.comInvestors in Royalty Pharma (NASDAQ:RPRX) have seen respectable returns of 40% over the past yearJune 29, 2025 | finance.yahoo.comRoyalty Pharma PLC (NASDAQ:RPRX) Holdings Raised by Robeco Institutional Asset Management B.V.June 29, 2025 | marketbeat.comAsset Management One Co. Ltd. Acquires 12,148 Shares of Royalty Pharma PLC (NASDAQ:RPRX)June 29, 2025 | marketbeat.comWall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to HoldJune 29, 2025 | marketbeat.comRPRX Royalty Pharma plc - Seeking AlphaJune 28, 2025 | seekingalpha.comRoyalty Pharma plc (RPRX) Balance Sheet - Yahoo FinanceJune 28, 2025 | finance.yahoo.comRoyalty Pharma PLC (NASDAQ:RPRX) Holdings Decreased by Overbrook Management CorpJune 28, 2025 | marketbeat.comRoyalty Pharma plc - Ordinary Shares - Class A RPRX OverviewJune 28, 2025 | money.usnews.comMarathon Asset Management Ltd Sells 68,924 Shares of Royalty Pharma PLC (NASDAQ:RPRX)June 28, 2025 | marketbeat.comRoyalty Pharma PLC (NASDAQ:RPRX) Shares Sold by Paragon Capital Management Inc.June 27, 2025 | marketbeat.com31,200 Shares in Royalty Pharma PLC (NASDAQ:RPRX) Acquired by Board of the Pension Protection FundJune 27, 2025 | marketbeat.com2 Surging Stocks to Research Further and 1 to Be Wary OfJune 26, 2025 | finance.yahoo.comPhillips Wealth Planners LLC Takes Position in Royalty Pharma PLC (NASDAQ:RPRX)June 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeJAZZ, AXSM, RPRX, and CORT Company DescriptionsAxsome Therapeutics NASDAQ:AXSM$106.66 +1.23 (+1.16%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Corcept Therapeutics NASDAQ:CORT$68.40 -3.87 (-5.35%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.Jazz Pharmaceuticals NASDAQ:JAZZ$107.71 -1.74 (-1.59%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.Royalty Pharma NASDAQ:RPRX$35.55 -0.82 (-2.25%) As of 03:05 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 commercial products and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, immunology, respiratory, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Warehouse Wars: Can BJ’s Take Advantage of Costco’s Weakness? Why Freeport-McMoRan Is The Copper King in a Tight Market Correction Equals Opportunity in Domino’s Pizza Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
